- Investing.com
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
Metrics to compare | 8QQ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship8QQPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −2.9x | −0.5x | |
PEG Ratio | 0.00 | 0.09 | 0.00 | |
Price/Book | 0.0x | 1.1x | 2.6x | |
Price / LTM Sales | 0.0x | 2.1x | 3.2x | |
Upside (Analyst Target) | 0.0% | 38.2% | 41.2% | |
Fair Value Upside | Unlock | 24.7% | 6.2% | Unlock |